Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
about
Risk Scoring to guide anti-platelet therapy post percutaneous coronary intervention (PCI) for acute-coronary syndrome (ACS) results in improved clinical outcomes.Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry.The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.The year in cardiology 2017: acute coronary syndromes.The year in cardiology 2017: coronary interventions.Optimal pharmacological therapy in ST-elevation myocardial infarction-a review : A review of antithrombotic therapies in STEMI.Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction.Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.Individualized Antiplatelet Therapy: A Long Way to Go.Comparative Review of Oral P2Y12 Inhibitors.Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study.De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary InterventionNovel aspects of antiplatelet therapy in cardiovascular disease
P2860
Q47617519-6CF2D624-C5C3-43CD-9E46-66EE6EF7ED2EQ47707224-ED0108F9-54BC-41C3-B9F0-F13E100D355AQ47865745-6A4F9D84-6CBD-4773-9654-3CBE207E7449Q50193541-471477E6-5670-4C0E-A877-FA5D49255AC1Q50193633-EB35CCB7-FA1A-43BB-9C69-99A44BA78086Q52567898-7FEF21C9-2B04-447F-A69C-DAF05EF39319Q52589129-CAFB3F17-DF1E-4856-9DD9-FF6C27DDAD9DQ52593402-0B467243-C1BD-435E-AA79-5AEED11A51C0Q55384929-793AD07C-A58D-4903-946D-03224D723FA0Q55396201-D9D789FE-60B3-4151-9A63-3CFA3B14BA0BQ55405593-6FC4FA83-2812-4EC5-9053-0528507E4CD3Q57143053-E8C95584-BBA2-4E58-AFFD-6472BB4E61B6Q57179203-1C508F37-9847-43B4-995A-97CA83BF9707
P2860
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Benefit of switching dual anti ...... ry syndrome) randomized study.
@en
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC
@nl
type
label
Benefit of switching dual anti ...... ry syndrome) randomized study.
@en
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC
@nl
prefLabel
Benefit of switching dual anti ...... ry syndrome) randomized study.
@en
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC
@nl
P2093
P2860
P356
P1476
Benefit of switching dual anti ...... ry syndrome) randomized study.
@en
P2093
Clémence Bassez
Guillaume Bonnet
Jacques Quilici
Jean Louis Bonnet
Jean Philippe Mouret
Laurent Fourcade
Marc Lambert
Marie Christine Alessi
Pierre Deharo
Pierre Emmanuel Morange
P2860
P304
P356
10.1093/EURHEARTJ/EHX175
P577
2017-05-16T00:00:00Z